Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Budesonide Foam (2 mg/25 mL BID for 2 Weeks, Followed by 2 mg/25 mL QD for 4 Weeks) Versus Placebo in Subjects With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Aug 2019
Price :
$35
*
At a glance
- Drugs Budesonide (Primary)
- Indications Ulcerative proctitis; Ulcerative proctosigmoiditis
- Focus Registrational; Therapeutic Use
- Sponsors Bausch Health Companies; Salix Pharmaceuticals
- 11 Oct 2013 Results will be presented at the American College of Gastroenterology (ACG) 2013 Annual Scientific Meeting according to a Salix Pharmaceuticals.
- 22 May 2013 Primary endpoint 'Significant difference between budesonide and placebo in remission rate' has been met, according to a Salix Pharmaceuticals media release.
- 22 May 2013 Top-line results published in a Salix Pharmaceuticals media release.